Member Info for elrico

Thanks, Aqua.

I decided to consign phat to the filter list some time ago, and I had to blacklist two of his email addresses for similar abuse.

Phat is not known for critical analysis; he is famous for his sarcasm, poor research, and lack of understanding of market dynamics.

If I were to make excuses for him, I guess it would be in the form of advising Phat to use Vision Express's services rather than his own franchise's. :)

Bel,

I had you pegged as a savvy investor. Yet you make a basic error. The TR1 issued is as a reduction as a result of the recent raise they didn’t take part in, which takes them under a previously stated percentage. Seneca will be releasing similar showing their increase because they took part in the placing. It’s just housekeeping.

Aqua,

Your in-specie should not be regarded as free money. OPTI investors lost value through a capital reduction of 56%. Sure, our PBX shares cost nil cash, but they came with a price proving very expensive given the devaluation in both assets.

Just for the record...SOH has destroyed PBX value in record time in a half @ssed attempt to save PLC costs by listing on Aquis. This fiasco will further damage SOH's reputation. I warned him this would happen. The handling of the lock-in has created a disorderly market, exacerbating the situation. It is a dam shame that sets OPTI and PBX back regarding investor sentiment. A heavy price for taking advice from idiots that only serve their own P\L.

Farris,

Your comments give readers like me the impression that you cannot read an RNS and digest its contents. Stuart and the board have a lot of plates spinning; that is true - it's called business planning. There are starter plates, dinner plates, and, I suspect, dessert plates around the table or in the kitchen.

You need to understand the pace is not governed by the speed of the waiter but by the chef; at least one head chef is rewriting the main course.

Bel,

I think I should offer Toyin a contributors slot. His response just about covers the current situation, as I understand it.

TC,

I believe neither Quentin Tarantino or Peter Jackson were available. Such a shame. :)

Clio,

The best way I can explain the apparent anomaly you speak of is by providing anecdotal info I am aware of from the past. In this case, a good friend of mine bought OPTI in the 70s.

From memory, so the details from several years.

Before this purchase, 111,111 shares (one of several) were declared to me several hours before the purchase—almost 24 hours.

1: On the day of this particular purchase, the shares were about 5% up on small volume.
2: 111,111 represented a tad over 1/3rd of the total volume.
3: My friend set a price lower than the offer
4: Broker had an excellent relationship with a particular MM
5: MM was able to walk the SP back in an attempt to flush weak holders
6: SP finished 5% lower

So how is this possible the SP swung c10% with a buy order?

As it happens, the purchase was reported later when the SP recovered. This gave the appearance that 111,111 was a sell and not a buy.

Not all trades are reported live. Also, not all trades are reported on the same day. MM can be tricky creatures, but they are not privy to inside info unless a Corp is corrupt.

I hope this helps.

DC,

I have the trolls filtered, so I don’t have a clue which one of the 8 it is.

Feeling blessed. :)

Boo hoo ?????

Have a good weekend.

TC,

Ref valuation of proposed acquisition: A basic rule of thumb (subject to sector variables, etc) is that c4x net profit is a reasonable best guess.

I know I opened the door on Derma as a possible acquisition target - I do not wish to nail my hat on one Company, as I mentioned two when I could have proposed a further two likely targets. However, Derma does have access to the NHS that others do not have, or if they do, I missed it. Moreover, Derma has sales via national pharmacy chains and multiple online pharmacies, with an impressive portfolio I would imagine could easily double with a new formula with SkinBiotix intel inside. I bet Cath and her team are working on this right now. :) This would have almost certainly formed part of the DD. Cath is switched on.

TC,

They are not private. I have set them to allow all comments from free and paid members.

Scinv_temp

With. respect, Sir. Don't blame investors with vision and a grasp of the business model for your lack of understanding of the same. It's a tad unfair. :)

Most investors will be aware that an early-stage bio has significant risks. But, the lead product has effectively been de-risked. It seems to be a matter of double-checking the quality of the data for errors.

POLB will be talking with potential partners, likely while they are in Cali and at the investment event. The Company has explained the business model and provided examples of licensing deals for the next phase. These are potentially huge, even multiples of the current market value.

NEW article https://tinyurl.com/yn8xckbf

Open source research
https://tinyurl.com/5yrxy57n

It adds considerable weight to my hypothesis. :)

https://lemminginvestor.substack.com/p/skinbiotherapeutics-plc-51e/comments

DC,

I think the RNS with the details imminent. How quickly the shares arrive in your broker account is anyone’s guess. This will depend on the custodian and respective brokers. We could get an RNS in the AM or next week confirming the details.

https://lemminginvestor.substack.com/publish

2 PBX articles this week.

I may need a liberal application of deep heat to ease the stitch you gave me, TC. lol

Aqua,

Let me clarify my view related to your quoted opinion; "I do find elric/elrico's pessimistic view of the sweetbiotix launch taking place as opposed to skinbiotix a little difficult to reconcile."

First of all, my pessimism is not aimed at OPTI/SweetBiotix product launch, but a reminder of what some commentators were leading investors to believe was inevitable before Christmas 2021. Namely, not one, but two commercial agreements could be announced, one at least. Remind me what was announced and when? Moreover, I have previously been very keen on SweetBiotix prospects as far back as the Summer of 2017; indeed, the SP rallied to 130p on the back of TW, promoting my second in-depth interview with SOH. The rest, as they say, is history.

In short, expectations for the successful launch of SweetBiotix were set by investors, which was my point. I accept I should have been clearer, but I assumed readers were well-versed in my opinion of the topic.

Croda has always been a three-year project and thus far remains on track. However, I accept there is some confusion on the timing of revenues from the deal, which is unfortunate, but outside SBTX's control.

I don't think it is helpful comparing SBTX with OPTI. They are different entities with different ambitions. IMHO, Croda looks likely to be ahead in terms of generating recurring revenues several years ahead of SweetBiotix's potential partners. However, we need to realise the exhaustive testing required for SweetBiotix; the same is not required for the lysate for various reasons.

I hope this clarifies my POV.

Thanks, TC.

All the very best for 2023 to you, sir, and everybody suffering my musings, such as they are. :)

I have always been impressed with SOH when he speaks of his strategic plans. He has a clear vision for the future. However, as the years pass by, as they have, you come to realise he is not in control of the roadmap or the timing of the journey, the big corps are, and that is the nature of the business when a small company seeking to do business with the big corps. So this has been the unwinding of the patience because product development has taken far longer than we expected, and that is partly down to investors not managing their own expectations, and in some cases (SweetBiotix in particular) has taken far, far longer than we had hope of based on SOH's language.

TC,

I am with you. A reach announcement would have been preferable. But, at the risk of sounding like I am making excuses for the board, I genuinely think they have more important tasks for January/February.